Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2005-02-17
2009-12-01
Wilson, James O (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
active
07626020
ABSTRACT:
The invention relates to compounds such aswhere P is a nitrogen-protecting group, and to processes for preparing these compounds.
REFERENCES:
patent: 5464853 (1995-11-01), Chan et al.
patent: 5514691 (1996-05-01), Chan et al.
patent: 5843902 (1998-12-01), Garnick et al.
patent: 6197967 (2001-03-01), Vollmueller et al.
patent: 2002/0055457 (2002-05-01), Janus et al.
patent: 2002/0107284 (2002-08-01), Uckun et al.
patent: 2003/0092757 (2003-05-01), Singh et al.
patent: 2005/0014769 (2005-01-01), Osswald et al.
patent: 0510526 (1992-10-01), None
patent: 0526708 (1993-02-01), None
patent: 0558258 (1993-09-01), None
patent: 0569193 (1993-11-01), None
patent: 0640596 (1995-03-01), None
patent: 0682016 (1995-11-01), None
patent: 0749964 (1996-12-01), None
patent: 1256344 (2002-11-01), None
patent: 1424080 (2004-06-01), None
patent: 2295616 (1996-06-01), None
patent: 94/27979 (1994-12-01), None
patent: 95/26957 (1995-10-01), None
patent: 96/09818 (1996-04-01), None
patent: 96/40681 (1996-12-01), None
patent: 98/40332 (1998-09-01), None
patent: 99/48530 (1999-09-01), None
patent: 99/55683 (1999-11-01), None
patent: 99/56761 (1999-11-01), None
patent: 00/21509 (2000-04-01), None
patent: 00/36918 (2000-06-01), None
patent: 00/67024 (2000-11-01), None
patent: 01/00198 (2001-01-01), None
patent: 01/44239 (2001-06-01), None
patent: 01/60370 (2001-08-01), None
patent: 01/91736 (2001-12-01), None
patent: 02/11713 (2002-02-01), None
patent: 02/49630 (2002-06-01), None
patent: 02/069906 (2002-09-01), None
patent: 02/074034 (2002-09-01), None
patent: 02/080960 (2002-10-01), None
patent: 02/085351 (2002-10-01), None
patent: 03/006041 (2003-01-01), None
patent: 03/009805 (2003-02-01), None
patent: 03/015820 (2003-02-01), None
patent: 03/039539 (2003-05-01), None
patent: 03/045434 (2003-06-01), None
patent: 2004/018044 (2004-03-01), None
patent: 2004/032922 (2004-04-01), None
patent: 2004/035057 (2004-04-01), None
patent: 2005/023264 (2005-03-01), None
patent: 2005/063735 (2005-07-01), None
patent: 2006/056760 (2006-06-01), None
patent: 2007/010235 (2007-01-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Morris, Michael J. et al., Clinical approaches to osseous metastases in prostate cancer, The Oncologist, 2003, pp. 161-173, vol. 8, No. 2.
Rosano, Laura A. et al., Therapeutic targeting of the endohelin a receptor in human ovarian carcinoma, Cancer Research, May 15, 2003, pp. 2447-2453, vol. 63, No. 10, XP002365689.
Walczak J. R. et al., Pharmacological Treatments for Prostate Cancer, Expert Opinion on Investigational Drugs, 2002, pp. 1737-1748, vol. 11, No. 12, XP009008862.
Rosano, Laura et al., ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances cytotoxicity of paclitaxel in human ovarian carcinoma in vitro and in vivo, Apr. 16-20, 2005, AACR, Anaheim/Orange County, CA.
Curtis, N. et al., ZD4054 specifically inhibits endothelin A receptor-mediated anti-apoptotic effects, but not endothelin B receptor-mediated pro-apoptotic effects, Sep. 28-Oct. 1, 2004, AACR-NCI-EORTC, Geneva, Switzerland.
Liu, Glenn et al., Tolerability profile of ZD4054 is consistent with the effects of endothelin A receptor-specific antagonism, May 13-17, 2005, ASCO Annual Meeting, Orlando, Florida.
Morris, C. et al., ZD4054: specificity for endothelin A receptor following single-dose administration in healthy volunteers, Sep. 28-Oct. 1, 2004, AACR-NCI-EORTC, Geneva, Switzerland.
Dreicer, R. et al., ZD4054 specifically inhibits endothelin A receptor-mediated effects but not endothelin B receptor-mediated effects, Feb. 17-19, 2005, ASCO Prostate Cancer Symposium, Orlando, Florida.
Todd, Martin et al., Metabolite Factories: Use of microbial systems to generate metabolites of an endothelin receptor antagonist, Jul. 3-8, 2005, Biotrans 2005, Delft, The Netherlands.
Morris, C.D. et al., Specific inhibition of the endothelin A receptor with ZD4054: clinical and preclinical evidence, British Journal of Cancer, 2005, 2148-2152, vol. 92.
Curtis, N. et al., ZD4054 blocks ET-1-stimulated phosphorylation of p44/42 mitogen-activated protein kinase and proliferation of osteoblast cells, Apr. 16-20, 2005, AACR, Anaheim/Orange County, CA.
Morris, C.D. et al, ZD4054 reduces endothelin-1-induced forearm vasoconstriction in healthy male volunteers, Apr. 16-20, 2005, AACR, Anaheim/Orange County, CA.
Rosano, Laura et al, Combined targeting of the endothelin receptor and the epidermal growth factor receptor in ovarian cancer shows enhanced antiproliferative effects, Apr. 1-5, 2006, AACR 2006, Washington, DC.
Curwen, J.O., ZD4054 : A specific endothelin A receptor antagonist with potential utility in prostate cancer and metastatic bone disease, European Journal of Cancer, Nov. 2002, p. S102, vol. 38, XP004403782.
Nelson, J.B., The role of endothelin-1 and endothelin receptor antagonists in prostate cancer, British Journal of Urology, 2000, pp. 45-48, 85, Suppl 2.
Endothelin Inhibitors: Exploring Novel Therapeutics, Symposium, Jun. 7-8, 1999, Washington, D.C., Iddb Meeting Report, Jun. 25, 1999.
Boven, E., American Society of Clinical Oncology—35th Annual Meeting (Part 1), Symposium, May 15-18, 1999, Atlanta, GA, Iddb Meeting Report, Sep. 13, 2001.
McKinnon, C., American Society of Clinical Oncology-35th Annual Meeting (Part IV), Symposium, May 15-18, 1999, Atlanta, GA, Iddb Meeting Report, Sep. 13, 2001.
Adeniyi, A., American Urological Association-94th Annual Meeting, Symposium, May 1-6, 1999, Dallas, TX, Iddb Meeting Report, Aug. 26, 1999.
McKinnon, C., Topoisomerase inhibitors and other new agents, ID Drugs, 1999, pp. 629-632, vol. 2, No. 7.
Adeniyi, A., American Urological Association-94th Annual Meeting May 1-6, 1999, Dallas, TX, ID Drugs, 1999, pp. 656-658 vol. 2, No. 7.
Boven, E., American Society of Clinical Oncology-35th Annual Meeting, May 15-18, 1999, Atlanta, GA, ID Drugs, 1999, pp. 617-619, vol. 2, No. 7.
Nelson, Joel B., Editorial: Endothelin Receptor Antagonists in the Treatment of Prostate Cancer, The Prostate, pp. 91-92, 2001, vol. 49.
Nelson, Joel B., The Role of the Endothelin Axis in Prostate Cancer, The Prostate Journal, pp. 126-130, 1999, vol. 1, No. 3.
Nelson, Joel B. et al, Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate, Nature Medicine, pp. 944-949, Sep. 1995, vol. 1, No. 9.
Carducci, Michael A. et al, Endothelin Receptor Antagonist, ABT-627, For Prostate Cancer: Initial Trial Results, The Journal of Urology, p. 176, 1999, vol. 161(4) Suppl.
Jarvis, Michael F., et al., ABT-627, an endothelin ETA receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain, European Journal of Pharmacology, pp. 29-35, 2000, vol. 388. No. 1.
Bagnato, Anna, et al., Autocrine Actions of Endothelilin-1 as a Growth Factor in Human Ovarian Carcinoma Cells, Clinical Cancer Research, 1995, pp. 1059-1066, vol 1.
Wu-Wong, Jinshyun R., Endothelin attenuates apoptosis in human smooth muscle cells, Biochemical Journal, pp. 733-737, 1997, vol. 328.
Spinella, Francesca, et al., Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1a in Ovarian Carcinoma Cells, The Journal of Biological Chemistry, pp. 27850-27855, Aug. 2, 2002, vol. 277, No. 31.
Kroodsma, J.M., et al., Endothelinen: modelijk een nieuw farmacologisch aangrijpingspunt bij hartvaatziekten, nierziekten en oncologische aandoingen, Nederlands Tijdschrift Voor Geneeskunde, 1997, pp. 1806-1810, vol. 141, Part 38.
Nelson, Joel B. et al., Endothelin-1 Production and Decreased Endothelin B Receptor Expression in Advanced Prostate Cancer, Journal of Cancer Research, Feb. 15, 1996, pp. 663-668, vol. 56.
Derwent AN 2001-565331, XP002271565.
Piettre, Serge R., et al., Monoaryl- and Bisaryldihydroxytropolones as Potent Inhibitors of Inositol Monophosphatase, Journal of Medicinal Chemistry, 1997, pp. 4208-4221, vol. 40.
Butlin Margaret Anne
Butlin Roger John
Hogan Philip John
Meudt Andreas
AstraZeneca AB
Murray Jeffrey H
Wilson James O
LandOfFree
Protected forms of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protected forms of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protected forms of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4113361